What is Desmopressin?
Desmopressin is a hormone analogue used in specific water-balance and related conditions. Its effects depend on the formulation and clinical setting.
Biological role or research focus
Water conservation through vasopressin-related signaling.
Its uses concern specific fluid-balance conditions. Product instructions and fluid precautions require clinical guidance.
Role reference: MedlinePlus · Desmopressin ↗
Names you may encounter
DDAVP
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Vasopressin analogue
- Main research area
- Water conservation
- Evidence featured
- Human randomized trial
- Source check
- October 4, 2026
Source: MedlinePlus · Desmopressin ↗
Quick answers
- Is Desmopressin FDA approved?
- Yes. DDAVP (e.g., NDA 019955) and generics for central diabetes insipidus and primary nocturnal enuresis. Source ↗
- Is Desmopressin safe?
- Approved antidiuretic hormone drug; its biggest danger is low blood sodium from water retention, which can cause seizures, coma or death if not caught. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Desmopressin banned in sport?
- Yes. The 2026 World Anti-Doping Agency (WADA) Prohibited List names it (S5 Diuretics and masking agents). Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Nocturia formulation study (2012) | Human randomized trial | 757 adults in the intention-to-treat population, mostly with excessive nighttime urine production. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2012
Nocturia formulation study
Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double-blind, placebo-controlled trial.
- Population / model
- 757 adults in the intention-to-treat population, mostly with excessive nighttime urine production.
- Study design
- Four-week placebo-controlled study of an orally disintegrating formulation.
- Main finding
- Nighttime voiding decreased and the first sleep period lengthened. Clinically important low sodium occurred in some treatment groups.
- Limits & context
- Formulation and patient selection matter. This study cannot supply instructions for a different desmopressin product, and fewer bathroom trips must be weighed against hyponatremia risk.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
83 registered studies name Desmopressin as an intervention among the 100 most recently updated of 127 search results; 13 are recruiting or under way, 2 have not started recruiting yet, 46 completed and 22 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.
| Study | Status | Phase | Start | People |
|---|---|---|---|---|
| Systematic Use of DDAVP to Prevent Serum Sodium Overcorrection in Severe Hyponatremia NCT06020495 · Assistance Publique - Hôpitaux de Paris | Recruiting | Phase 3 | 2024-12-17 | 260 |
| FESS With or Without Intranasal Desmopressin in Chronic Rhinosinusitis With Nasal Polyps NCT07855315 · Services Institute of Medical Sciences, Pakistan | Not yet recruiting | Not applicable | 2026-10-15 | 174 |
| Prophylactic Desmopressin Before Native Kidney Biopsy in Severe Renal Impairment NCT07840313 · Sindh Institute of Urology and Transplantation | Completed | Not applicable | 2017-08-01 | 250 |
| DDAVP Effect by TEG6 in Cardiac Surgery NCT07179991 · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Recruiting | 2026-08-01 | 100 | |
| Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome NCT06635629 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Recruiting | Phase 2 | 2024-12-12 | 140 |
| Bedtime Device Restriction and Desmopressin in PMNE. NCT07776977 · Al-Azhar University | Recruiting | Not applicable | 2026-08-20 | 140 |
| Randomized Controlled Clinical Study on the Prophylactic Intraoperative Use of Desmopressin in Complex Sellar Region Tumors NCT07712328 · Zhaoyun Zhang | Enrolling by invitation | Phase 4 | 2026-06-02 | 152 |
| Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial NCT06337838 · Hamilton Health Sciences Corporation | Recruiting | Phase 3 | 2025-06-09 | 100 |
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 83 listed studies.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Desmopressin. ↗
· 2006 · Review
Desmopressin. ↗
· 2023 Jan · Study Guide
Desmopressin and antifibrinolytics. ↗
International anesthesiology clinics · 1990 Fall · Journal Article, Review
Intranasal desmopressin-induced hyponatremia. ↗
Pharmacotherapy · 1996 Jan-Feb · Case Reports, Journal Article, Review
Risks & interactions
Approved antidiuretic hormone drug; its biggest danger is low blood sodium from water retention, which can cause seizures, coma or death if not caught.
This entry follows the label for one brand (Desmoda); desmopressin is sold in several forms, and some other desmopressin products carry a boxed warning for low sodium. Evidence comes from clinical studies and postmarketing reports.
Take extra care with: Heart or blood pressure problemsKidney problems
From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.
Who should not use it
- People with low blood sodium now or in the past
- People allergic to desmopressin or any ingredient
- People with moderate to severe kidney impairment
Interactions
- SSRI or tricyclic antidepressants and chlorpromazine: higher risk of low sodium
- Thiazide diuretics, NSAIDs and opioid pain relievers: higher risk of low sodium
- Carbamazepine, lamotrigine, chlorpropamide and oxybutynin: higher risk of low sodium
- Other blood-vessel-narrowing drugs (vasoconstrictors): blood pressure may rise
Serious risks
- Low blood sodium (water intoxication) that can cause seizures, coma, breathing arrest or death
- Higher low-sodium risk in children, older adults, and during illness, heat, hard exercise or heavy fluid intake
- Fluid retention that can worsen heart failure or uncontrolled high blood pressure
- Severe allergic reactions, including fatal anaphylaxis reported with other desmopressin forms
- Toxicity risk in newborns from a benzyl alcohol-related preservative in this product
Common side effects
- headache
- nausea
- vomiting
- diarrhea
- abdominal cramps
- fatigue
- dizziness
- swelling
Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Desmoda (desmopressin acetate) prescribing information ↗
Key precautions
Retaining too much water can lower blood sodium dangerously. Fluid intake, kidney function, interacting medicines, and sodium monitoring are central clinical considerations.
Source: MedlinePlus · Desmopressin ↗
Regulatory status
- U.S. FDA approval
- Approved
DDAVP (e.g., NDA 019955) and generics for central diabetes insipidus and primary nocturnal enuresis; Desmoda (NDA 219873) approved February 2026. Several older brands (Stimate, Noctiva, Nocdurna, Minirin) are listed as discontinued. source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source - World Anti-Doping Agency (2026)
- Prohibited, named on the list · S5 Diuretics and masking agents
Named explicitly ("Desmopressin") as a masking agent; prohibited at all times. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Clinical uses & product context
The oral medication reference covers central diabetes insipidus, certain post-injury or postsurgical symptoms, and bedwetting. The study below concerns a distinct orally disintegrating nocturia formulation. Their instructions are not interchangeable.
Source: MedlinePlus · Desmopressin ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
This is a prescription medicine, available only with a prescription through a pharmacy. Versions sold online as "research" products are not the approved medicine, and the FDA has warned sellers of them, so PepsRadar does not list, compare or link them. See the official product information linked in References.
Mechanism & research rationale
It replaces aspects of vasopressin signaling, helping the body conserve water and balance salt and fluid. This concerns water handling rather than glucose lowering.
Source: MedlinePlus · Desmopressin ↗
Molecular structure
Questions worth asking
- Which indication and formulation does the source describe?
- Does the video make a broader claim than the source supports?
- Its uses concern specific fluid-balance conditions. Product instructions and fluid precautions require clinical guidance.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Is diabetes insipidus the same as diabetes mellitus?
No. The former concerns water regulation; the latter concerns blood-glucose regulation.
Source: MedlinePlus · Desmopressin ↗
Can one formulation’s study determine another product’s use?
No. Product-specific absorption, indication, and precautions must be checked.
References & editorial record
- MedlinePlus · Desmopressin ↗
- Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double-blind, placebo-controlled trial. ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
